Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | VNN1 | O95497 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431433 | 0.82 | GRM5 (0.53) | KDM1AL3MBTL3HPGDL3MBTL1GRM5 | |
| SCHEMBL27713265 | 0.79 | SFRP1 (0.46) | L3MBTL3HPGDSFRP1ADRA1AHPGDS | |
| SCHEMBL4736618 | 0.79 | RAB9A (0.58) | L3MBTL3HPGDSFRP1L3MBTL1GRM5 | |
| SCHEMBL1808354 | 0.78 | ALDH1A1 (0.51) | GRM5 | |
| SCHEMBL27713264 | 0.78 | GPR119 (0.45) | KDM1AL3MBTL3HPGDSFRP1ADRA1A | |
| SCHEMBL1136719 | 0.77 | L3MBTL3 (0.59) | L3MBTL3HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL4616149 | 0.77 | NAMPT (0.54) | SFRP1ADRA1AHPGDSGPR119VNN1 | |
| SCHEMBL4732920 | 0.76 | MAPT (0.54) | L3MBTL3HPGDL3MBTL1GPR119 | |
| SCHEMBL2425225 | 0.76 | NOS1 (0.55) | KDM1AL3MBTL3L3MBTL1GPR119GRM5 | |
| SCHEMBL4615984 | 0.76 | ALDH1A1 (0.62) | L3MBTL3HPGDSFRP1ADRA1AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008061016-A1 | N-SUBSTITUTED PIPERIDINYL 4 -ARYLSULFONAMIDES AS MODULATORS OF THE SECRETED FRIZZLED RELATED PROTEIN- 1 | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | KDM1A 2105/4885L3MBTL3 4802/4885HPGD 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.